The use of opioids in the treatment of chronic pain is widespread; the prevalence of specific opioids varies from country to country and depends on product availability, national formulary systems, and provider preferences. Patients often receive opioids for legitimate treatment of pain conditions, but on the opposite side of the spectrum, nonmedical use of opioids is a significant public health concern.
INTRODUCTION
Chronic nonmalignant pain is experienced by 20-40% of adults, and cancer pain by up to 70% of oncology patients [1, 2] . Opioids are routinely employed in pain treatment for both etiologies, despite a lack of data to characterize potential implications of long-term use for nonmalignant pain [1, 3] . The United States (US) ranks 3rd for opioid consumption per capita, with hydrocodone and oxycodone most commonly prescribed [4] . Despite increasing use of opioid analgesics, pain is still frequently undertreated in the US and around the world [4, 5] .
Oxycodone/naloxone (OXN) prolongedrelease (PR) is indicated for treatment of severe pain requiring treatment with opioids; a low dose of naloxone added to the fixed-dose combination (FDC) antagonizes opioid receptors in the gastrointestinal tract, providing relief of opioid-induced constipation (OIC) [6] . OXN is the first product with a dual mechanism for achieving opioid analgesia while targeting the underlying cause of OIC, thus proactively addressing constipation symptoms. OXN was initially approved in Germany in 2006 and is now approved for use in 36 countries. Currently, it is under review by the Food and Drug Administration for approval in the US [7] . This review will explore the utility of OXN for use in pain management while providing relief of OIC, and implications of potential abuse deterrence.
METHODS
A literature search was conducted in the MEDLINE database using term ''oxycodone and naloxone'' through December 2013. All clinical and pharmacokinetic studies and reviews of OXN (as the FDC or separate formulations) were included. The MEDLINE search generated 177 results, with 59 containing relevant information for OXN. A search on clinicaltrials.gov for ''oxycodone and naloxone'' was performed in December 2013, and additional references were identified in published bibliographies. This review does not contain any new studies with human or animal subjects performed by any of the authors. 
OPIOID-INDUCED CONSTIPATION

PHARMACOECONOMIC CONSIDERATIONS
Results from industry-sponsored costeffectiveness analyses favored OXN over oxycodone PR in the United Kingdom (UK), Germany, Spain, Belgium, and the Netherlands [74] [75] [76] [77] [78] . The German study [76, 77] [84, 85] . In the second report [86] , poor analgesia and symptoms of withdrawal were documented in a patient with portal vein thrombosis after converting oxycodone PR to OXN 20/10 mg/day. The authors hypothesized that absorption of naloxone via portosystemic collateral channels bypassed first-pass hepatic metabolism, resulting in increased bioavailability of naloxone [86] . These cases support employing vigilance when prescribing OXN to patients requiring high doses or rapid titration. OXN is contraindicated in patients with moderate to severe hepatic impairment as systemic exposure with naloxone may be increased. Additionally, OXN has not been studied in pregnant or lactating women.
Naloxone crosses the placenta, and fetal exposure could result in opioid withdrawal [46] . OXN use has been explored for other conditions, including restless leg syndrome symptoms refractory to first-line dopaminergic treatment [87] . Studies for use with other indications have been recently completed or are underway (e.g., Clinicaltrials.gov #NCT01197261, #NCT01374763, #NCT01816581, #NCT01439100, #NCT00944697).
OPIOID MISUSE AND ABUSE DETERRENCE
In light of increasing levels of nonmedical use, the risks and benefits of prescribing controlled substances must always be carefully considered [88, 89] . Individuals may abuse opioids via several different modes of administration, with oral, IV, and intranasal identified as the most common routes [90] . Some formulations readily lend themselves to overuse via the intended route (e.g., IR oxycodone and hydrocodone).
Other medications are appealing due to the ability of users to overcome the PR mechanisms to achieve a better ''high'' by administration through an alternative route. Experienced opioid abusers are known to tamper with formulations to accelerate drug delivery by injection or insufflation, but the oral route is preferred by the vast majority (up to 97% of abusers) [90] . Abusers have identified oxycodone as a drug of preference due to its variety of available formulations [91] ; consequently, abuse-deterrent formulations such as OXN may be of great clinical importance.
Abuse-deterrent strategies are typically targeted at discouraging tampering attempts and limiting administration by non-approved routes such as injection, which may carry increased risks to the abuser (e.g., overdose, infection, drug dependence) [92] . Tamper resistance (i.e., physical barriers), inclusion of irritants, aversive components, formulation of a prodrug, and unique delivery systems are all employed in efforts to dissuade abuse [93, 94] .
Combining an opioid agonist with an antagonist may discourage tampering or administration by unapproved routes [90, 94] .
It is important to note that abuse-deterrent mechanisms do not preclude all forms of abuse and may lead to unpredictable upswings in abuse of other drugs [95, 96] . Furthermore, the addition of an orally inactive antagonist may not discourage abuse by oral ingestion [97] . Abuse-deterrent mechanisms are, however, an important component of efforts to dissuade nonmedical use and limit ingestion by high-risk routes of administration. It has been suggested that OXN may provide abuse deterrence, though no peer-reviewed studies are available as of this writing. It has been suggested that increased systemic exposure of naloxone, antagonism of opioid effects, and reduced drug liking when the drug is chewed or administered via intranasal and IV routes may reduce the appeal of OXN for experienced opioid abusers [98] [99] [100] [101] . The manufacturer is seeking language about abuse deterrence on the product label in the US [7] .
CONCLUSIONS
OXN is a promising addition to the armamentarium of treatment options for chronic pain of cancer and nonmalignant etiology. Naloxone does not appear to impair analgesic efficacy for the vast majority of patients, and benefit for the treatment of OIC has been clearly demonstrated. The role for OXN in OIC prevention compared to standard prophylaxis with laxatives has yet to be determined. OXN use for prevention in at-risk populations may be prudent given the high burden and relative under-appreciation of OIC's impact, and provide greater cost efficiency by reducing costs associated with OIC. As prescription drug misuse with oxycodone and other opioids has grown to epidemic proportions in the US, the presence of naloxone as an abuse-deterrent feature may potentially confer additional benefit, particularly for oxycodone abusers who prefer non-oral routes of ingestion. It is unclear how the presence of naloxone will affect abusers who prefer to ingest large quantities of the drug orally. More research on the impact of abuse deterrence for this formulation is needed. 
